Antibodies for the treatment of cancers

Patent metadata

Field	Value
Publication number	US-11053310-B2
Application number	US-201615780334-A
Country	US
Kind code	B2
Filing date	Dec 5, 2016
Priority date	Dec 4, 2015
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

Provided herein are novel anti-EMP2 antibodies useful for the treatment and diagnosis of cancers that express or overexpress EMP2. In one aspect, provided herein is an isolated antibody that binds to Epithelial Membrane Protein 2 (EMP2), that includes heavy chain variable region and a light chain variable region. The heavy chain variable region includes three heavy chain complementary determining regions (HCDRs) and the light chain variable region includes three light chain variable regions (LCDRs). In some embodiments, the sequence of HCDR1 is SEQ ID NO: 11, the sequence of HCDR2 is SEQ ID NO: 12, the sequence of HCDR3 is SEQ ID NO: 13, the sequence of LCDR1 is SEQ ID NO:14, the sequence of LCDR2 is SEQ ID NO: 15, and the sequence of LCDR3 is SEQ ID NO: 16.

First claim

We claim:

1. An isolated antibody that binds to Epithelial Membrane Protein 2 (EMP2), comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain variable regions (LCDRs), wherein: the sequence of HCDR1 is SEQ ID NO:11, the sequence of HCDR2 is SEQ ID NO:12, the sequence of HCDR3 is SEQ ID NO:13, the sequence of LCDR1 is SEQ ID NO:14, the sequence of LCDR2 is SEQ ID NO:15, and the sequence of LCDR3 is SEQ ID NO:16.

2. The antibody of claim 1 , wherein the antibody comprises the heavy chain variable region comprising the amino acid sequence according to SEQ ID NO:3 and the light chain variable region comprising the amino acid sequence according to SEQ ID NO:4.

3. The antibody of claim 2 , wherein the antibody comprises a heavy chain comprising the amino acid sequence according to SEQ ID NO:6 and a light chain comprising the amino acid sequence to SEQ ID NO:7.

4. The antibody of claim 1 , wherein the antibody is an scFv, a diabody, minibody, or triabody, a chimeric antibody, or a recombinant antibody.

5. The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic agent or a label.

6. A pharmaceutical composition comprising the antibodies of claim 1 and a physiologically acceptable carrier.

7. A method of treating or reducing the rate of reoccurrence of an EMP2 expressing cancer in a patient, the method comprising:
administering to the patient an effective amount of an anti-EMP2 antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three heavy chain complementary determining regions (HCDRs) and wherein the light chain variable region comprises three light chain variable regions (LCDRs), wherein: the sequence of HCDR1 is SEQ ID NO:11, the sequence of HCDR2 is SEQ ID NO:12, the sequence of HCDR3 is SEQ ID NO:13, the sequence of LCDR1 is SEQ ID NO:14, the sequence of LCDR2 is SEQ ID NO:15, and the sequence of LCDR3 is SEQ ID NO:16.

8. The method of claim 7 , wherein the antibody comprises the heavy chain variable region comprising the amino acid sequence according to SEQ ID NO:3 and the light chain variable region comprising the amino acid sequence according to SEQ ID NO:4.

Assignees

• Univ California

Inventors

• Wadehra Madhuri
• Braun Jonathan

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• G01N2333/705

  Assays involving receptors, cell surface antigens or cell surface determinants · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title